Search Results
Your search for Hope matches 3186 pages
Showing 1101 - 1150Assessing the Progress Made in Global Cancer Care and Looking Toward the Future
In October 2020, Her Royal Highness Princess Dina Mired of Jordan ended her 2-year tenure as President of the Union for International Cancer Control (UICC), a global organization with more than 1,198 members from 172 countries and territories committed to reducing the cancer burden and...
ASH 2020: Early Signs of Risk for Myeloproliferative Neoplasms May Appear in Childhood or in Utero
Genetic mutations linked to myeloproliferative neoplasms may emerge in childhood or even in utero, decades before they cause cancer, according to a late-breaking abstract presented today at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition by Jyoti Nangalia, MBBChir, and ...
ASH 2020: Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL
Results from a phase II study presented by Nicholas J. Short, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 464) showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab...
Expert Point of View: David Snyder, MD
David Snyder, MD, Acting Chair, City of Hope Department of Hematology & Hematopoietic Cell Transplantation, Duarte, California, who was not involved in the ASCEMBL study, commented on the promise of asciminib: “The hope is this drug would be able to overcome resistance to other tyrosine kinase...
ASH 2020: Role of Venetoclax in High-Risk Myeloid Malignancies
The BCL2 inhibitor venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers, and in early studies, the combination showed improved outcomes, according to two reports presented by Jacqueline S. Garcia, MD, and colleagues at the 2020 American Society of Hematology ...
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplant May Improve Survival in Older Patients With High-Risk MDS
Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a survival benefit from stem cell transplant. As...
Social Needs May Be Linked to Low Health-Related Quality of Life Among Black Cancer Survivors
Social needs—such as food and economic insecurity, poor housing and neighborhood conditions, and lack of access to transportation—were common in a group of Black cancer survivors in Detroit. These factors were associated with lower health-related quality of life, according to findings published by...
Does Concurrent Treatment With Dexamethasone Diminish the Efficacy of Immune Checkpoint Inhibitors in Patients With Glioblastoma?
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to results of a study published by Iorgulescu et al in Clinical Cancer Research....
ASCO Launches Educational Series on Social Determinants of Health
As part of its ongoing commitment to addressing inequities in cancer care and research, ASCO has launched an educational series focused on the role of social determinants of health in cancer care and outcomes. The free series, which kicked off in October, will help educate oncology trainees and...
ELNEC Project Reaches Historic Milestone in End-of-Life Care
The End-of-Life Nursing Education Consortium (ELNEC) project is ending 2020 by surpassing a goal established 20 years ago, reporting more than 1 million nurses and other professionals trained using the ELNEC curriculum. Administered through a partnership between the American Association of Colleges ...
Rogel Team at University of Michigan Receives $11.2M to Leverage the Microbiome Against Graft-vs-Host Disease
A team of researchers from the University of Michigan Rogel Cancer Center in Ann Arbor received an $11.2 million grant from the National Heart, Lung, and Blood Institute to study how to use the microbiome to limit complications of stem cell transplants for blood cancers and other diseases....
Yes, Men Get Breast Cancer, Too
You could call it a sixth sense, but the moment I felt a lump in my left breast I knew it was cancer, although it would take several weeks to confirm the diagnosis. When I saw my primary cancer physician and told him of my concern, he said: “Don’t worry. Men don’t get breast cancer; it’s a woman’s...
This Year’s FDA-ASCO Workshop Focused on Collection of Patient-Reported Tolerability Data From Clinical Trials
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Vishal Bhatnagar, MD, Associate Director for Patient Outcomes, Bellinda King-Kallimanis, PhD, Senior Staff...
Growing Interest in Antiandrogens to Treat Male Breast Cancer
“There has been a lot of interest in the development of new antiandrogens” for clinical use in patients with breast cancer,” Anthony D. Elias, MD, reported in an update on male breast cancer at the 2020 Lynn Sage Breast Cancer Symposium, sponsored by the Robert H. Lurie Comprehensive Cancer Center...
Expert Point of View: Howard (Jack) West, MD, and William R. Sellers, MD
Howard (Jack) West, MD, Associate Clinical Professor in Medical Oncology at City of Hope Comprehensive Cancer Center, Duarte, California, was impressed with the data from the KRYSTAL-1 trial. “It’s great to see new data on another entrant into the space for patients with KRAS G12C...
Nagi S. El Saghir, MD, FACP, FASCO, Receives Lebanon’s National Cedar Medal Award
One of Lebanon’s highest national awards, the National Cedar Medal (Commander Rank), was recently bestowed upon Nagi S. El Saghir, MD, FACP, FASCO, in recognition of his extensive contributions to the fields of medicine, education, and science—and most particularly, for his efforts in the fight...
Impact of COVID-19 on Cancer Care in India
With the announcement of a complete nationwide lockdown on March 25, 2020, to prevent the spread of COVID-19, a lot of unprecedented events came into being in India. The National Health Mission reported a 69% reduction in measles, mumps, and rubella vaccination in children; a 21% reduction in...
Novel Treatment Approaches on the Horizon in Multiple Myeloma
Clinicians who treat multiple myeloma can anticipate a host of new treatments: melflufen, cereblon E3 ligase modulators (CELMoDs), antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Kenneth C. Anderson, MD, FASCO, Director of the Jerome Lipper...
Guideline Update Offers New Directions About Trastuzumab Emtansine for HER2-Positive Breast Cancer
About 10% to 20% of newly diagnosed breast cancers demonstrate overexpression of the HER2 protein.1 Since the introduction of trastuzumab, several new HER2-targeted therapies have been approved for use in the adjuvant and metastatic settings (eg, pertuzumab, lapatinib, and neratinib). However, for...
Optimizing the Treatment of Adults With Acute Lymphoblastic Leukemia
In the treatment of adults with acute lymphoblastic leukemia (ALL), use of newer antibodies and de-intensification of chemotherapy have greatly improved outcomes, according to Hagop Kantarjian, MD, FASCO, who has been very involved in much of the research in ALL treatment. Dr. Kantarjian, Professor ...
Study Finds the Lung Microbiome May Affect Tumor Progression and Prognosis in Patients With Lung Cancer
A new study by Tsay et al sheds light on the role the lung microbiome may play in lung cancer pathogenesis and prognosis. According to the study’s findings, enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression....
Your Stories: ‘Being Your Own Advocate’
Kimberly Irvine was used to taking care of the people she loved. Conquering breast cancer—twice—forced the young mom to learn how to take care of herself in a whole new way. In the Your Stories episode “Being Your Own Advocate,” she shares with fellow philanthropist Riccardo Braglia, Board Member, ...
COVID-19’s Impact on Cancer Care Around the World: Perspectives From the ASCO International Affairs Committee
As the world continues to respond to the COVID-19 pandemic, ASCO is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that patients with cancer receive high-quality care. Here, members of the ASCO International Affairs...
My Age May Have Been a Barrier to Timely Diagnosis of Glioblastoma Multiforme
I think my age and apparent good health contributed to a delay in my diagnosis of glioblastoma multiforme. The first symptom I had of the cancer appeared on December 26, 2014, when I was 32 years old. My family and I had just gotten home from celebrating the Christmas holiday with our relatives...
Beyond BROCADE3: Just the Beginning for Veliparib-Based Therapy in Advanced BRCA-Mutated Breast Cancer
As recently reported in The Lancet Oncology and reviewed in the October 10, 2020, issue of The ASCO Post, the phase III BROCADE3 trial has shown that the addition of veliparib to carboplatin and paclitaxel improved progression-free survival in previously treated BRCA-mutated advanced breast...
Predicting Cardiovascular Disease Risk Via Routine CT Scans in Women With Breast Cancer
Coronary artery calcification scores based on routine computed tomography (CT) scans used for planning radiotherapy therapy may be able to predict which women with breast cancer have a high probability of developing cardiovascular disease. The promise of this research is that once high-risk...
Using Meaning-Centered Interventions to Address Suffering on the Cancer Journey
A large body of research has shed light on how the cancer experience and related losses often leave patients and their families struggling to find a sense of meaning in their lives.1-7 The COVID-19 pandemic has amplified these difficulties, as meaningful activities and experiences have been...
PALOMA-3 Exploratory Analysis: Who Benefits Most From Palbociclib?
The phase III PALOMA-3 trial significantly reduced the risk of disease progression by 50% in patients with hormone receptor–positive/HER2-negative advanced breast cancer, but the improvement in overall survival did not reach statistical significance.1 An exploratory subgroup analysis has now shown...
As a Young Oncologist, Enrique Soto Pérez de Celis, MD, MSc, Met a Career-Changing Mentor at the ASCO Annual Meeting
Geriatric oncologist and researcher Enrique Soto Pérez de Celis, MD, MSc, was born in Mexico City and grew up in the nearby city of Puebla. “There were no physicians in the family who might have influenced my decision to become a doctor, but both of my parents were academics; my mother was a...
Chronic Lymphocytic Leukemia: New Treatments Achieve Deeper Remissions
At the National Comprehensive Cancer Network® (NCCN®) 2020 Virtual Congress: Hematologic Malignancies, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, reviewed current data on chronic lymphocytic leukemia (CLL), including promising new combinations of modern...
Richard Pazdur, MD, Awarded the Simon M. Shubitz Cancer Prize and Lectureship
For more than 4 decades, the University of Chicago Cancer Research Foundation’s Simon M. Shubitz Cancer Prize and Lectureship has honored an internationally renowned individual for his or her exceptional contributions to cancer research and clinical care. The recipient of this year’s award is...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Chile
Chile has a population of approximately 19 million living predominantly in urban areas (87.7%), with a population density of 66 inhabitants per square mile.1 For the year 2020, approximately 12% of its population was older than 65 years.1 Socioeconomic Trends and Cancer The country has experienced ...
New Maintenance Therapies in Metastatic Pancreatic Cancer Aim to End Perpetual Chemotherapy
The advent of effective combination chemotherapies has changed the treatment landscape for metastatic pancreatic cancer, extending median survival and leading to durable responses in a subset of patients. However, perpetual chemotherapy is cumulatively toxic, leading to progressive bone marrow...
USPSTF Issues Draft Recommendation on Screening for Colorectal Cancer
On October 27, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement on screening for colorectal cancer. For the first time, the Task Force is recommending that screening start at age 45. This is a B recommendation, meaning the USPSTF recommends the service; that...
Remembering Patrick H. Beauregard: ‘Selfless in His Efforts to Raise Awareness’ of Colorectal Cancer in Young Adults
The editors of The ASCO Post are sad to report the death of Patrick H. Beauregard on September 6, 2020. The cause was colorectal cancer. Diagnosed with stage IV disease in 2017 at the age of 29, Mr. Beauregard dedicated the last 3 years of his life to raising awareness of colorectal cancer in...
Personal Testimonial: CAR-modified T Cells in Adults
Twelve adults with chronic lymphocytic leukemia (CLL) have been treated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy at the University of Pennsylvania in Philadelphia by Carl June, MD, Richard W. Vague Professor in Immunotherapy, and colleagues. These were all end-stage...
Preliminary Progress with Genetically Engineered T Cells in Treating Childhood ALL
Two small phase I studies at separate centers demonstrated encouraging results in the treatment of children with acute lymphoblastic leukemia (ALL) using reinfused autologous genetically engineered T cells. Results of both studies were presented at the Annual Meeting of the American Association for ...
Breast Cancer and Radiation Researcher David Gius, MD, PhD, Joins Mays Cancer Center
David Gius, MD, PhD, a breast cancer and radiation researcher, has joined the Mays Cancer Center, home to The University of Texas Health San Antonio MD Anderson. He was recruited to the Mays Cancer Center from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University with a $6...
A Gritty Journey Into a Rare Cancer and Back
Over the past decade, a prolific number of cancer memoirs have been published, and some have been award-winning bestsellers. When entering a crowded genre, it is best to have something that sets your story apart. Judith Dwyer Fugate did just that with a memoir about a rare tumor that has rarely if...
Advanced Melanoma: Lenvatinib Plus Pembrolizumab After Disease Progression on Anti–PD-1 Therapy
Checkpoint inhibitors can be lifesaving for many patients with advanced melanoma, but those who experience disease progression currently have few treatment options. The combination of a tyrosine kinase inhibitor and an anti–PD-1 agent may offer some hope in this setting, according to a study of...
City of Hope Launches Innovative Support Model for Employers
City of Hope in Duarte, California, announced the formal launch of AccessHope, a wholly owned subsidiary dedicated to serving employers and their health-care partners. Instead of requiring patients to travel to City of Hope, AccessHope exports insights from National Cancer Institute–level...
Expert Point of View: Sjoukje Oosting, MD, PhD
Invited discussant of the xevinapant study, Sjoukje Oosting, MD, PhD, of the University Medical Center Groningen, the Netherlands, commented: “There is finally hope on the horizon that we can increase the cure rate of our patients with head and neck cancer, if these data are confirmed in a phase...
COVID-19, Cancer, and the Older Adult
An inspiring case series of fit patients aged 98 and older who recovered from hospitalization for COVID-19, published by Huang et al, reminds us that older age may not be a barrier to recovery.1 On behalf of the Cancer and Aging Research Group, we do not support “ageism” in the care of older...
ASCO Approves First Joint MSTS/ASTRO/ASCO Guideline on Treatment of Metastatic Carcinoma and Myeloma of the Femur
On June 20, 2020, ASCO approved the first joint Musculoskeletal Tumor Society (MSTS)/American Society for Radiation Oncology (ASTRO)/ASCO guideline on the care of patients with metastatic carcinoma and myeloma of the femur.1 Guideline recommendations were based on a systematic review of clinical...
Making Strides in the Management of Pancreatic Cancer
The Special Conference on Pancreatic Cancer, sponsored by the American Association for Cancer Research (AACR) and held virtually this year, showcased cutting-edge discoveries and promising advances in the understanding and treatment of pancreatic cancer, reported by some of the world’s foremost...
Art of Oncology: On the Page and in a Podcast, Personal Reflections From Oncologists Are a Fitting Companion Amid the COVID-19 Pandemic
The well-loved Art of Oncology section of the Journal of Clinical Oncology (JCO) and its pioneering podcast are both resonating as never before, as cancer specialists are prompted into deeper reflections about the poignant moments that give life meaning by the COVID-19 pandemic. JCO’s Art of...
A Leader in Drug Development, Patricia Keegan, MD, Reflects on Making a Difference in Cancer Care
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Patricia Keegan, MD, who served at the U.S. Food and Drug Administration (FDA) for 30 years, most recently as Acting Associate Director of Medical Policy at the Oncology Center for Excellence (OCE)....
Expert Point of View: Camillo Porta, MD
Acknowledging there are now expanded therapeutic choices in the first-line setting for advanced renal cell carcinoma, formal study discussant Camillo Porta, MD, of the University of Bari Aldo Moro, Italy, said that studies of the immunotherapy combinations could not be compared directly. “We should ...
LUNGevity Foundation Recognizes Recipients of 2020 Career Development Awards
LUNGevity Foundation, a nonprofit organization, recently announced three recipients of its 2020 Career Development Awards for lung cancer research. These awards were presented to Kathyrn Arbour, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center; Carl Gay, MD, PhD, of The University...
City of Hope Hires Stephen Gruber, MD, PhD, MPH, to Head Its Center for Precision Medicine
Cancer geneticist Stephen Gruber, MD, PhD, MPH, has joined City of Hope as Director of its newly founded Center for Precision Medicine. He will lead a team of more than 14 researchers who will work across the institution to pioneer personalized cancer prevention and treatment plans. As a medical...
